Ustekinumab

A biologic that blocks the inflammatory proteins IL-12 and IL-23. Started by drip, then injected under the skin.

Also called: stelara, pyzchiva, wezenla, uzpruvo, steqeyma, otulfi, imuldosa, usymro, yesintek, ustekinamab

Related words interleukin inhibitor biologic

Topics Biologics and newer medicines

Questions people ask

Which biologic is best for Crohn's?

There is no single best biologic for everyone. Trials comparing two drugs directly are still few: SEAVUE found ustekinumab and adalimumab worked about equally well in people new to biologics, and SEQUENCE found risankizumab was better than ustekinumab at healing the bowel in people for whom anti-TNF drugs had not worked. A 2026 Cochrane review comparing all the options says more head-to-head trials are needed.

Sources

What is a biologic medicine?

Crohn's & Colitis UK explains that biologics are antibody medicines made by living cells in a lab. Each one targets a specific part of the immune system involved in inflammation: anti-TNFs (infliximab, adalimumab), the anti-integrin vedolizumab, and interleukin blockers (ustekinumab, risankizumab, mirikizumab, guselkumab). They are given by drip or by injection under the skin. Upadacitinib is a 'targeted' tablet, not a biologic.

Sources

Which biologics and targeted medicines are approved for Crohn's on the NHS?

NICE has approved infliximab and adalimumab (TA187), vedolizumab (TA352), ustekinumab (TA456), risankizumab (TA888), upadacitinib (TA905), mirikizumab (TA1080) and guselkumab (TA1095) for Crohn's, each under certain conditions. Most of the newer ones are for people whose disease has not responded to, or cannot have, an earlier treatment. Your IBD team decides with you which is suitable.

Sources

Where to read more

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Systematic review May 2025 Patients and professionals

Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.

Topics Biologics and newer medicines

Jargon explained IL-12/23 induction certainty of evidence

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)

New England Journal of Medicine Study Jul 2024 Patients and professionals

A head-to-head trial in people whose Crohn's had not responded to, or who could not tolerate, anti-TNF drugs. Risankizumab (Skyrizi) was at least as good as ustekinumab (Stelara) for remission at 24 weeks and better at healing the bowel lining by 48 weeks. Side effects looked similar.

Topics Biologics and newer medicines Research

Jargon explained non-inferiority endoscopic remission anti-TNF

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)

The Lancet Study Jun 2022 Patients and professionals

One of the first 'head-to-head' trials comparing two biologics directly, in people who had never had a biologic. At one year, about 65% on ustekinumab and 61% on adalimumab were in remission, a difference too small to matter. Both worked well, so the choice between them can depend on other things such as preference and how the drug is given.

Topics Biologics and newer medicines Research

Jargon explained head-to-head trial biologic-naive confidence interval

Starting biologic medication

Royal Free London NHS Foundation Trust Leaflet Aug 2025 For patients

A patient leaflet for people starting a biologic for IBD. It explains what biologics are, when they are used (often after steroids or azathioprine have not worked), and lists the biologics used at the hospital, their brands and how each is given.

Topics Biologics and newer medicines

Jargon explained biologic infusion biosimilar

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

NICE Guideline Aug 2025 For professionals

NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.

Topics Biologics and newer medicines Medicines

Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment

Guselkumab

Crohn's & Colitis UK Guide Dec 2025 For patients

A guide to guselkumab (Tremfya), an IL-23 blocking medicine. The first three doses can be a drip or an injection, after which it is injected under the skin; the page covers vaccines and side effects.

Topics Biologics and newer medicines

Jargon explained IL-23 interleukin inhibitor

Search everything for "ustekinumab"